Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
Etravirine is an enzyme inducer and could lower the concentration of combined drugs. Ten HIV-1-infected patients with multiple treatment failure received raltegravir (400 mg, twice daily) and darunavir/ritonavir (600/100 mg, twice daily). Addition of etravirine (200 mg, twice daily) leads to a significant increase in raltegravir and darunavir trough concentrations (405 vs. 118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine.
AP-HP, Hospital Bicêtre, Paris, France. aurelie.barrail-tran@bct.aphp.fr
Aurélie
A
Barrail-Tran
Yazdan
Y
Yazdanpanah
Lauriane
L
Goldwirt
Geneviève
G
Chêne
Céline
C
Colin
Christophe
C
Piketty
Diane
D
Bollens
Christine
C
Katlama
Diane
D
Descamps
Jean-Michel
JM
Molina
Catherine
C
Fagard
Anne-Marie
AM
Taburet
D000293:Adolescent; D000328:Adult; D000069454:Darunavir; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011724:Pyridazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011743:Pyrimidines; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D055815:Young Adult
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D013449:Sulfonamides; C451734:etravirine; D019438:Ritonavir; D000069454:Darunavir